Phase 4 Atrial Fibrillation Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged 18 or older
- People who have recently had a successful procedure to open blocked heart arteries (called PCI, either as an emergency or planned procedure)
- People who have been diagnosed with an irregular heart rhythm called atrial fibrillation or atrial flutter — either previously or within 72 hours of the procedure — and who have a long-term need (at least 1 year) for blood-thinning medication
Who may not be able to join:
- People who cannot take the blood-thinning medication edoxaban, aspirin, or all medications in the P2Y12 inhibitor group (a type of blood thinner)
- People who need blood-thinning medication for a reason other than atrial fibrillation or flutter (for example, blood clots in the legs or lungs)
- People who have had a stroke within the past 12 months
- People with a very high score on a heart risk scale called CHADSVASc (score of 7 or above)
- People with a moderate to severe narrowing of one of the heart valves (the mitral valve)
- People who have an artificial mechanical heart valve
- People with a blood clot inside the heart or a specific type of heart bulge requiring blood thinners
- People with very poor heart pumping function combined with confirmed slow blood flow in the heart
- People who have ever had bleeding inside the brain
- People who are actively bleeding at the time of enrolment
- People with a history of bleeding inside the eye, spine, abdomen area, or into a joint from an injury — unless the cause of that bleeding has been permanently fixed
- People who have had a gastrointestinal bleed (such as stomach or bowel bleeding) within the past month, unless the cause has been permanently fixed
- People with a known condition that affects blood clotting
- People with severe anaemia needing a blood transfusion, or a very low platelet count (below 50 × 10⁹/L)
- People with a BMI over 40, or who have had weight-loss (bariatric) surgery
- People with severe kidney failure (eGFR below 15)
- People with active liver disease or active hepatitis A, B, or C
- People with an active cancer (excluding a common, low-risk type of skin cancer called non-melanoma skin cancer)
- People with a life expectancy of less than 1 year
- People who are pregnant or breastfeeding
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Jurriën M ten Berg, Prof, MD, St. Antonius Hospital
Phone: +31 (0)88 320 0925
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Primary safety endpoint; Primary efficacy endpoint
Can't join this trial?
Data last synced from ClinicalTrials.gov: 7 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.